Evidence map›Paper›PMID 31099056›Full record

ArticleClinical and experimental immunology2019

IL-1 receptor antagonist, anakinra, prevents myocardial dysfunction in a mouse model of Kawasaki disease vasculitis and myocarditis.

M Gorelik, Y Lee, M Abe, T Andrews, L Davis, J Patterson, S Chen, T R Crother, G J Aune, M Noval Rivas and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Innate and adaptive immunity in acute myocarditis.International journal of cardiology · 2024
    Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Kawasaki Disease-Associated Cytokine Storm Syndrome.Advances in experimental medicine and biology · 2024
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

M GorelikDepartment of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX, USA.
Y LeeDivision of Pediatric Infectious Diseases and Immunology, Burns and Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
M AbeDivision of Pediatric Infectious Diseases and Immunology, Burns and Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
T AndrewsDivision of Pediatric Hematology and Oncology, University of Texas Health Science Center, San Antonio, TX, USA.
L DavisDivision of Pediatric Hematology and Oncology, University of Texas Health Science Center, San Antonio, TX, USA.
J PattersonDepartment of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX, USA.
S ChenDivision of Pediatric Infectious Diseases and Immunology, Burns and Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
T R CrotherDivision of Pediatric Infectious Diseases and Immunology, Burns and Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
G J AuneDivision of Pediatric Hematology and Oncology, University of Texas Health Science Center, San Antonio, TX, USA.
M Noval RivasDivision of Pediatric Infectious Diseases and Immunology, Burns and Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0001-5570-8928
M ArditiDivision of Pediatric Infectious Diseases and Immunology, Burns and Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0001-9042-2909
University of California, Los Angeles · USThe University of Texas Health Science Center at San Antonio · USAllen Institute · USTexas Biomedical Research Institute · US

Funding

Role of IL-1 in Bacterial ligand-induced vasculitis and myocarditisR01AI072726 · NIAID · CEDARS-SINAI MEDICAL CENTER · PI ARDITI, MOSHE · 2008 to 2020
$4.5M
Role of intestinal microbiome and gut permeability in the development of Kawasaki Disease vasculitisR01HL139766 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI Magali Noval Rivas · 2018 to 2026
$3.4M
Innate Immunity and Pathogen mediated Acceleration in Vascular InflammationR01HL111483 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI CHEN, SHUANG · 2012 to 2016
$2.0M
NHLBI NIH HHS R01 HL139766NIAID NIH HHS R01 AI072726
6 · The paper itself

Abstract

Kawasaki disease (KD) vasculitis is an acute febrile illness of childhood characterized by systemic vasculitis of unknown origin, and is the most common cause of acquired heart disease among children in the United States. While  histological evidence of myocarditis can be found in all patients with acute KD, only a minority of patients are clinically symptomatic and a subset demonstrate echocardiographic evidence of impaired myocardial function, as well as increased left ventricular mass, presumed to be due to myocardial edema and inflammation. Up to a third of KD patients fail to respond to first-line therapy with intravenous immunoglobulin (IVIG), and the use of interleukin (IL)-1 receptor antagonist (IL-1Ra, anakinra) is currently being investigated as an alternative therapeutic approach to treat IVIG-resistant patients. In this study, we sought to investigate the effect of IL-1Ra on myocardial dysfunction and its relation to myocarditis development during KD vasculitis. We used the Lactobacillus casei cell-wall extract (LCWE)-induced murine model of KD vasculitis and investigated the effect of IL-1Ra pretreatment on myocardial dysfunction during KD vasculitis by performing histological, magnetic resonance imaging (MRI) and echocardiographic evaluations. IL-1Ra pretreatment significantly reduced KD-induced myocardial inflammation and N-terminal pro B-type natriuretic peptide (NT-proBNP) release. Both MRI and echocardiographic studies on LCWE-injected KD mice demonstrated that IL-1Ra pretreatment results in an improved ejection fraction and a normalized left ventricular function. These findings further support the potential beneficial effects of IL-1Ra therapy in preventing the cardiovascular complications in acute KD patients, including the myocarditis and myocardial dysfunction associated with acute KD.

Indexed as

AnimalsCardiomyopathiesDisease Models, AnimalImmunoglobulins, IntravenousInflammationInterleukin 1 Receptor Antagonist ProteinLacticaseibacillus caseiMaleMiceMice, Inbred C57BLMucocutaneous Lymph Node SyndromeMyocarditisNatriuretic Peptide, BrainReceptors, Interleukin-1VasculitisImmunoglobulins, IntravenousInterleukin 1 Receptor Antagonist ProteinNatriuretic Peptide, BrainReceptors, Interleukin-1anakinraechocardiogramIL-1IL-1RaKawasaki diseaseMRImyocardial edemamyocarditisNT-proBNPvasculitis

Identifiers

PMID31099056
PMCPMC6718290
OpenAlexW2946487803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.